Health TidingsRay Therapeutics Secures RMAT for RTx-015 in RP Ray Therapeutics Secures RMAT for RTx-015 in RP Read Post »
Health TidingsCogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Cogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Read Post »
Health TidingsFDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... FDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... Read Post »
Clinical TrialsPepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study PepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study Read Post »
New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Lilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Read Post »
Health TidingsAgios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Agios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Read Post »
Clinical TrialsOcugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Ocugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Read Post »
Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health BioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health Read Post »
Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Axsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Read Post »
GenericsFrom Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... From Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... Read Post »
Health TidingsScholar Rock Resubmits Apitegromab BLA to FDA Scholar Rock Resubmits Apitegromab BLA to FDA Read Post »
Drugs Safety AlertFDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) FDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) Read Post »
Clinical TrialsAstra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Astra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Read Post »
Health Tidings Mergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Biogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Read Post »
Health Tidings Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Galapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Read Post »
Clinical TrialsConnect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Connect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Read Post »
